Market Place
Sourcing Support
PTC Therapeutics’ Waylivra receives Brazilian regulatory approval
02 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Enforcement Report - Week of July 6, 2022
06 Jul 2022 //
FDA
BIORCHESTRA appoints pharma veteran and Moderna and Akcea CMO
23 Sep 2021 //
PRNEWSWIRE
Ionis cuts jobs at a former spinout and inks new deal with Sobi
07 Apr 2021 //
BIOPHARMADIVE
Nearly 70% of Akcea`s workforce is on the chopping block as Ionis
06 Apr 2021 //
ENDPTS
WAYLIVRA?, the First and Only Therapy for Familial Chylomicronaemia
09 Nov 2020 //
BUSINESSWIRE
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts
06 Nov 2020 //
BUSINESSWIRE
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical
04 Nov 2020 //
PRNEWSWIRE
Ionis and Akcea announce that Pfizer has a Pha2b clinical study of vupanorsen
03 Nov 2020 //
PRNEWSWIRE
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen)
29 Oct 2020 //
PRNEWSWIRE
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
12 Oct 2020 //
BIOSPACE
NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use
21 Sep 2020 //
PHARMA PHORUM
NICE u-turn sees Akcea`s Waylivra win NHS funding
18 Sep 2020 //
PHARMATIMES
Akcea`s WAYLIVRA® (volanesorsen) to Be Available on the NHS in England
18 Sep 2020 //
BUSINESSWIRE
Akcea’s board managed to get Ionis to boost its buyout bid a bit
15 Sep 2020 //
ENDPOINTS
Phase 2 Results on AKCEA-APO(a)-LRx Presented
02 Sep 2020 //
PRESS RELEASE
Ionis, changing its strategy, reels its spinoff back in
31 Aug 2020 //
BIOPHARMADIVE
Akcea, Ionis Pharma present positive data from phase 2 trial of vupanorsen
30 Aug 2020 //
PHARMABIZZ
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx))
28 Aug 2020 //
PRNEWSWIRE
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen
24 Aug 2020 //
PRESS RELEASE
Akcea and Ionis to Present Ph2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking
17 Aug 2020 //
PRNEWSWIRE
Akcea Announces New Pricing and Reimbursement of WAYLIVRA®
13 Aug 2020 //
PRNEWSWIRE
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen)
22 Jul 2020 //
PRNEWSWIRE
Akcea Appoints SVP, Global Medical Affairs
20 Jul 2020 //
CONTRACTPHARMA
Mallinckrodt`s kidney failure med squeaks by FDA panel 8-7
15 Jul 2020 //
FIERCEBILOTECH
Akcea Announces Appointment of New Chief Medical Officer
08 Jul 2020 //
PRNEWSWIRE
Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
29 Jun 2020 //
PRNEWSWIRE
Akcea Appoints New Senior Vice President, Business Development
08 Jun 2020 //
PRNEWSWIRE
Akcea announces approval for reimbursement of TEGSEDI®inotersen
07 Jun 2020 //
PRNEWSWIRE
Akcea announces approval for reimbursement of TEGSEDI® (inotersen)
01 Jun 2020 //
PRNEWSWIRE
Akcea & Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI®
28 May 2020 //
PHARMIWEB
Akcea Canada Confirms Letter of Intent with Pan-Canadian Alliance for inotersen
13 May 2020 //
NEWSWIRE
Akcea Expands Leadership Team with Appointment of Carla Poulson as SVP
07 May 2020 //
PRNEWSWIRE
Akcea, Pfizer hit midphase goal, but data raise doubts
29 Jan 2020 //
FIERCE BIOTECH
Akcea & Ionis report positive topline ph 2 study results of AKCEA-ANGPTL3-LRx
28 Jan 2020 //
GLOBENEWSWIRE
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
22 Jan 2020 //
PR NEWSWIRE
Retrotope Expands its Drug Pipeline with the First Dosing of RT001
09 Jan 2020 //
GLOBE NEWSWIRE
Biogen, Novartis go different ways on Ionis therapies
19 Dec 2019 //
BIOPHARMADIVE
As it shops for new deals, Akcea hires former GSK exec as COO
04 Dec 2019 //
END PTS
Akcea, Ionis begin NEURO-TTRansform phase 3 trial for AKCEA-TTR-LRx
25 Nov 2019 //
PHARMABIZ
Akcea taps first commercial chief as Waylivra debuts and pipeline advances
05 Nov 2019 //
FIERCEP PHARMA
Akcea Therapeutics Appoints Chief Commercial Officer
24 Oct 2019 //
CONTRACT PHARMA
After leadership shuffle, Akcea hands heart drug to Pfizer for $250M
08 Oct 2019 //
FIERCE BIOTECH
Ex-Ionis/Akcea exec Sarah Boyce takes charge at Avidity
02 Oct 2019 //
FIERCE BIOTECH
Ionis CBO takes over Akcea as CEO, CBO and COO head out the door
24 Sep 2019 //
FIERCE BIOTECH
SMC rejects Orkambi, accepts four medicines
13 Aug 2019 //
PHARMA TIMES
Final NICE guidance issued for Akcea’s Tegsedi
24 May 2019 //
PHARMA TIMES
Akcea`s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR
23 May 2019 //
PHARMAFILE
Ionis, Akcea`s Waylivra approved in EU after FDA rejection
09 May 2019 //
FIERCE PHARMA
NICE recommends Akcea`s Tegsedi for rare, life-threatening progressive disease
17 Apr 2019 //
PHARMAFILE
Akcea steals march on Alnylam with NICE approval
17 Apr 2019 //
PMLIVE
Novartis pays $150M to license Akcea-Ionis cardiac disease drug
26 Feb 2019 //
FIERCE BIOTECH
Unfazed by recent cardio setbacks, Novartis takes another PhIII Akcea drug
25 Feb 2019 //
ENDPTS
FDA rejects rare disease drug developed by Cambridge`s Akcea
28 Aug 2018 //
BIZ JOURNALS
